| Registro completo |
| Provedor de dados: |
BJPS
|
| País: |
Brazil
|
| Título: |
Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
|
| Autores: |
Liu,Lun-Fei
Chen,Ji-Su
Shen,Ji-Yang
Dou,Ting-Ting
Zhou,Jiong
Cai,Sui-Qing
Zheng,Min
|
| Data: |
2018-01-01
|
| Ano: |
2018
|
| Palavras-chave: |
Psoriasis
Ustekinumab/efficacy
Biologic agents
|
| Resumo: |
Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a fully human monoclonal antibody targeting the p40 subunit of both IL-12 and IL-23, has proven to be efficient and safe for treating patients with psoriasis. Yet, there have been no reports with human skin/blood samples that would elucidate the molecular mechanisms by which ustekinumab calms psoriasis skin lesions. To investigate the efficacy and molecular pathway (RORC, t-BOX and GATA) of ustekinumab in treating patients with psoriasis skin lesions. A total of 30 patients with psoriasis were randomized into placebo group and treatment group. PASI of each patient was calculated at 0, 12 and 24 weeks post-treatment. The mRNA levels of RORC, t-BOX and GATA in peripheral blood mononuclear cells separated from patients’ whole blood were analyzed using qPCR. Decreased mRNA of RORC, t-BOX and GATA were observed after continuous injections, indicating that ustekinumab exerts its effect by interacting with these molecules; while no significant difference in foxp3 mRNA levels were found between placebo group and treatment group.
|
| Tipo: |
Info:eu-repo/semantics/article
|
| Idioma: |
Inglês
|
| Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000400615
|
| Editor: |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
|
| Relação: |
10.1590/s2175-97902018000417349
|
| Formato: |
text/html
|
| Fonte: |
Brazilian Journal of Pharmaceutical Sciences v.54 n.4 2018
|
| Direitos: |
info:eu-repo/semantics/openAccess
|
